

Ref no: 161040216
From: Commercial
Date: 04/02/16
Subject: Gonadorelin (GnRH) Analogues

REQUEST & RESPONSE

We would like to request the following information regarding the administration of gonadorelin (GnRH) analogues (also known as LHRH analogues) for the treatment of prostate cancer within: St Helens and Knowsley Teaching Hospitals NHS Trust

- 1 Within your organisation, which healthcare professional (role) clinically recommends the LHRH that is prescribed?
Medical staff or CNS's according to protocols
- 2 Which healthcare professional (role) within your organisation usually administers the first injection?
The majority of patients are referred to primary care for their first injection. If patients do have their first injection within the Trust then the CNS administers this.
- 3 Where is the first injection usually given (hospital or primary care)?
Primary care
- 4 Which healthcare professional (role) within your organisation usually administers subsequent injections?
Again, the majority of patients have subsequent injections in primary care but if the small number that do attend hospital have their injection administered by the CNS's.
- 5 Where are subsequent injections usually given (hospital or primary care)?
Primary care
- 6 For subsequent injections, does the patient still remain under the care of the hospital (eg attends hospital clinics although injections are given in primary care), and if so, for how long?
Yes the patient still remains under the care of the hospital even though injections are given in primary care. If the patient is on hormone treatment alone, they stay under the care of the hospital indefinitely, if it is hormones given as part of EBRT, they may be discharged to their

GP at 5 years after treatment if they are stable. At this time hormones will have been discontinued.

- 7 If injections are administered in primary care, what recommendation/advice comes from the hospital?

We monitor the pt for side effects etc in clinic and advise primary accordingly dependant on what the pt reports

Pts on long term treatment- GP's are advised to monitor BP, bone density, blood sugars and vasomotor symptoms

8 Request for Re-use

Please can you confirm whether we are permitted to reuse any information provided under the Open Government Licence?

We (IMS Health) request permission to re-use as a part of an independent analysis into NHS administration of gonadorelin analogues, which has been commissioned by one of our clients.

The contents of the report **will not** be made available publically, but may be used by other IMS Health Group entities and service suppliers. The information in the report will be presented in a factual manner with all publication details staying true to the publisher.

We acknowledge that information provided may be protected by copyright and will include a copyright statement to this effect at the end of any information we publish if requested by you.